Published in Drug Week, June 16th, 2006
"We continue to make progress developing our product portfolio, with Evoltra (clofarabine), Modrenal and Suvus, which may become significant value drivers for the company in the future," commented Christopher B. Wood, MD, chairman and CEO of Bioenvision. "We are delighted especially with the CHMP Positive Opinion in the E.U.'s centralized process and look forward to our European marketing launch of Evoltra in the near future.
"We hope to continue the Evoltra development process with a filing for approval with the EMeA in H2 2006 in elderly patients with AML who...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.